SCHEMBL1032736

SCHEMBL1032736

CC#Cc1cc(C=O)n([C@H]2C[C@H](O)[C@@H](COC(c3ccccc3)(c3ccccc3)c3ccccc3)O2)c1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TYMP P19971 6/20 0.48
TYMS P04818 3/20 0.36
DUT P33316 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1035008 0.83 MEN1 (0.31) TYMP
SCHEMBL12768231 0.81 LMNA (0.43)
SCHEMBL1035161 0.81 LMNA (0.43)
SCHEMBL12768232 0.81 TK1 (0.36)
SCHEMBL3493524 0.77 TYMP (0.54) TYMPTYMS
SCHEMBL26647607 0.72 TYMS (0.53) TYMPTYMS
SCHEMBL26647537 0.72 TYMS (0.53) TYMPTYMS
SCHEMBL3511040 0.71 TYMP (0.48) TYMPTYMS
SCHEMBL6334503 0.71 POLB (0.58) TYMP
SCHEMBL10446716 0.71 POLB (0.58) TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2275538-B1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY TAGCYX BIOTECHNOLOGIES (JP) 2016-10-05 EP disclosed
US-8426569-B2 DNA capable of being amplified by PCR with high selectivity and high efficiency RIKEN (JP) 2013-04-23 US disclosed
US-20110053782-A1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY RIKEN (JP) 2011-03-03 US disclosed
EP-2275538-A1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY Riken (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053782-A1 NOVEL DNA CAPABLE OF BEING AMPLIFIED BY PCR WITH HIGH SELECTIVITY AND HIGH EFFICIENCY POLRMT, POLN, POLL TYMP 99/4885TYMS 71/4885DUT 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.